tbuckley/cabot-search huggingface dataset:
Care Pathways Before First Diagnosis of a Psychotic Disorder in Adolescents and Young Adults
Authors: Gregory E. Simon, Christine Stewart, Enid M. Hunkeler, Bobbi Jo Yarborough, Frances Lynch, Karen J. Coleman, Arne Beck, Belinda H. Operskalski, Robert B. Penfold, David S. Carrell
Journal: American Journal of Psychiatry (2018)

Objective: The authors sought to describe patterns of health care use prior to first diagnosis of a psychotic disorder in a population-based sample. Method: Electronic health records and insurance claims from five large integrated health systems were used to identify 624 patients 15–29 years old who received a first diagnosis of a psychotic disorder in any care setting and to record health services received, diagnoses assigned, and medications dispensed during the previous 36 months. Patterns of utilization were compared between patients receiving a first diagnosis of a psychotic disorder and matched samples of general health system members and members receiving a first diagnosis of unipolar depression. Results: During the year before a first psychotic disorder diagnosis, 29% of patients had mental health specialty outpatient care, 8% had mental health inpatient care, 24% had emergency department mental health care, 29% made a primary care visit with a mental health diagnosis, and 60% received at least one mental health diagnosis (including substance use disorders). Compared with patients receiving a first diagnosis of unipolar depression, those with a first diagnosis of a psychotic disorder were modestly more likely to use all types of health services and were specifically more likely to use mental health inpatient care (odds ratio=2.96, 95% CI=1.97–4.43) and mental health emergency department care (rate ratio=3.74, 95% CI=3.39–4.53). Conclusions: Most patients receiving a first diagnosis of a psychotic disorder had some indication of mental health care need during the previous year. General use of primary care or mental health services, however, does not clearly distinguish people who later receive a diagnosis of a psychotic disorder from those who later receive a diagnosis of unipolar depression. Use of inpatient or emergency department mental health care is a more specific indicator of risk.
Differential regulation of SOCS genes in erythroid cells - Lyn downregulates SOCS-1 and SOCS-3
Authors: Peta Tilbrook, M.P.K. Sarna, W Lepere, Evan Ingley, D.J. Mccarthy, James Williams, D.J. Hilton, R. Starr, Peter Klinken
Journal: Blood (2000)
Association of parental supply of alcohol with adolescent drinking, alcohol-related harms, and alcohol use disorder symptoms: a prospective cohort study
Authors: Richard P Mattick, Philip J Clare, Alexandra Aiken, Monika Wadolowski, Delyse Hutchinson, Jackob Najman, Tim Slade, Raimondo Bruno, Nyanda McBride, Kypros Kypri, Laura Vogl, Louisa Degenhardt
Journal: The Lancet Public Health (2018)

BackgroundSome parents supply alcohol to their children, reportedly to reduce harm, yet longitudinal research on risks associated with such supply is compromised by short periods of observation and potential confounding. We aimed to investigate associations between parental supply and supply from other (non-parental) sources, with subsequent drinking outcomes over a 6-year period of adolescence, adjusting for child, parent, family, and peer variables.MethodsWe did this prospective cohort study using data from the Australian Parental Supply of Alcohol Longitudinal Study cohort of adolescents. Children in grade 7 (mean age 12 years), and their parents, were recruited between 2010 and 2011 from secondary schools in Sydney, Perth, and Hobart, Australia, and were surveyed annually between 2010 and 2016. We examined the association of exposure to parental supply and other sources of alcohol in 1 year with five outcomes in the subsequent year: binge drinking (more than four standard drinks on a drinking occasion); alcohol-related harms; and symptoms of alcohol abuse (as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edition [DSM-IV]), alcohol dependence, and alcohol use disorder (as defined by DSM-5). This trial is registered with ClinicalTrials.gov, number NCT02280551.FindingsBetween September, 2010, and June, 2011, we recruited 1927 eligible parents and adolescents (mean age 12·9 years [SD 0·52]). Participants were followed up until 2016, during which time binge drinking and experience of alcohol-related harms increased. Adolescents who were supplied alcohol only by parents had higher odds of subsequent binge consumption (odds ratio [OR] 2·58, 95% CI 1·96–3·41; p<0·0001), alcohol-related harm (2·53, 1·99–3·24; p<0·0001), and symptoms of alcohol use disorder (2·51, 1·46–4·29; p=0·0008) than did those reporting no supply. Parental supply of alcohol was not significantly associated with the odds of reporting symptoms of either alcohol abuse or dependence, compared with no supply from any source. Supply from other sources was associated with significant risks of all adverse outcomes, compared with no supply, with an even greater increased risk of adverse outcomes.InterpretationProviding alcohol to children is associated with alcohol-related harms. There is no evidence to support the view that parental supply protects from adverse drinking outcomes by providing alcohol to their child. Parents should be advised that this practice is associated with risk, both directly and indirectly through increased access to alcohol from other sources.FundingAustralian Research Council, Australian Rotary Health, Foundation for Alcohol Research and Education, National Drug and Alcohol Research Centre.
Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single-centre study
Authors: M. Giannella, R. Pascale, A. Toschi, G. Ferraro, E. Graziano, F. Furii, M. Bartoletti, S. Tedeschi, S. Ambretti, R.E. Lewis, P. Viale
Journal: Clinical Microbiology and Infection (2018)
Atorvastatin directly improves vascular redox state by affecting eNOS coupling and NADPH-oxidase activity in human vein grafts ex-vivo
Authors: C Bakogiannis, C Antoniades, D Tousoulis, M Demosthenous, C Psarros, N Sfyras, K M Channon, C Stefanadis
Journal: Cardiovascular Research (2010)
Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML
Authors: Naval Daver, Guillermo Garcia-Manero, Sreyashi Basu, Jorge E. Cortes, Farhad Ravandi, Elias J. Jabbour, Rita Assi, Mark Brandt, Sherry Pierce, Tauna Gordon, Naveen Pemmaraju, Michael Andreeff, Jing Ning, Steven Kornblau, Tapan Kadia, Wilmer Flores, Jairo Matthews, Courtney D. DiNardo, Gautam Borthakur, Marina Konopleva, James Allison, Padmanee Sharma, Hagop M. Kantarjian
Journal: Blood (2017)
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2018–19 Influenza Season
Authors: Lisa A. Grohskopf, Leslie Z. Sokolow, Karen R. Broder, Emmanuel B. Walter, Alicia M. Fry, Daniel B. Jernigan
Journal: MMWR Recommendations and Reports (2018)

This report updates the 2013 recommendations by the Advisory Committee on Immunization Practices (ACIP) regarding use of seasonal influenza vaccines. Updated information for the 2014-15 influenza season includes 1) antigenic composition of U.S. seasonal influenza vaccines; 2) vaccine dose considerations for children aged 6 months through 8 years; and 3) a preference for the use, when immediately available, of live attenuated influenza vaccine (LAIV) for healthy children aged 2 through 8 years, to be implemented as feasible for the 2014-15 season but not later than the 2015-16 season. Information regarding issues related to influenza vaccination not addressed in this report is available in the 2013 ACIP seasonal influenza recommendations.
Electrophysiologic evaluation of antiarrhythmic drugs on supraventricular tachyarrhythmias.
Authors: Kazumasa Hiejima, Fumio Suzuki, Masaki Takahashi, Shutaro Satake
Journal: Circulation (1983)

The effects of the intravenous administration of three drugs, i.e., verapamil, disopyramide, and procainamide, on paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (Af) and atrial flutter (AF) were evaluated electrophysiologically. Efficacy on PSVT was 94.7% (36/38) with verapamil, 61.5% (13/18) with disopyramide and 100% (4/4) with procainamide. Efficacy on Af and AF was 9.1% (1/11) with verapamil and 80.0% (12/15) with disopyramide. PSVT termination mechanisms were as follows: 1) Verapamil: A-H block in 5 cases and H-A block in 5 cases with Type 1 A-V nodal reentrant tachycardia (AVNRT). H-A block in 6 cases with Type 2 and Type 3. A-H block in 17 of 18 cases with A-V reciprocating tachycardia (AVRT). Cycle length alternans were observed in 13 of 34 cases. 2) Disopyramide: H-A block in 2 cases with AVNRT and V-A block in 2 cases with AVRT. 3) Procainamide: V-A block in 4 cases with AVRT. These results suggest that verapamil and disopyramide are most effective on PSVT and Af, respectively.
Efficacy of infliximab in the treatment of Erdheim-Chester disease
Authors: Fleur Cohen-Aubart, Philippe Maksud, Jean-François Emile, Neila Benameur, Frédéric Charlotte, Philippe Cluzel, Zahir Amoura, Julien Haroche
Journal: Annals of the Rheumatic Diseases (2018)

Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterised by long bones and various other organs’ involvements.1 Tissues are infiltrated by CD68+ CD1a− foamy histiocytes.2 Therapeutic options are pegylated interferon-α,3 cladribine,4 mTOR inhibitors5 and anakinra in mild forms of ECD.6 7 Conversely, targeted BRAF or MEK inhibitor therapies are used for refractory or life-threatening ECD manifestations.8 9 All these therapies have frequent side effects. Interferon-α leads to fatigue, cytopenias and autoimmune diseases. Anakinra needs subcutaneous daily injections, with frequent local intolerance. Targeted therapies cause skin cancers, QT allongement, rhabdomyolysis and haemorrhage,10 and we lack long-term safety data with these drugs. Moreover, targeted therapies are not available in all countries. Thus, there is an unmet need for improving treatments in many patients with ECD, particularly in countries where access to targeted therapies is complicated or impossible.

Although our comprehension of this disease has recently moved from inflammatory to clonal myeloproliferative disease,11 the accumulation of pathological histiocytes leads to an increase of several cytokines in blood and affected tissues. Cytokine/chemokine network has been described in ECD lesions, and most of these factors are regulated by tumour necrosis factor alpha (TNF-α), which is also expressed in ECD lesions and serous fluids like pericardial effusion12–14 and has been implicated in ECD pathogenesis in in vitro models.15 Two ECD patients with cardiovascular involvement were successfully treated with infliximab, a TNF-α monoclonal chimeric antibody, achieving an improvement of symptoms, cardiac involvement and function.14 We aim to determine the efficacy of infliximab in a larger series of patients with ECD.

We retrospectively reviewed …
Predictors of Vascular Events and Disease Transformation in Chinese Patients with Myeloproliferative Neoplasms during Long-Term Follow-up
Authors: Garret Mk Leung, Jamilla Li, Karen Tang, Rita Yim, Ho-Wan Ip, Jason Chi Chiu So, Rock Y.Y. Leung, Clarence C.K. Lam, Yok-Lam Kwong, Harinder Gill
Journal: Blood (2017)
Computational Analysis of Epidermal Growth Factor Receptor Mutations Predicts Differential Drug Sensitivity Profiles toward Kinase Inhibitors
Authors: Sravani Akula, Swapna Kamasani, Sree Kanth Sivan, Vijjulatha Manga, Dashavantha Reddy Vudem, Rama Krishna Kancha
Journal: Journal of Thoracic Oncology (2018)
Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study
Authors: Gabriel A Brat, Denis Agniel, Andrew Beam, Brian Yorkgitis, Mark Bicket, Mark Homer, Kathe P Fox, Daniel B Knecht, Cheryl N McMahill-Walraven, Nathan Palmer, Isaac Kohane
Journal: BMJ (2018)

To quantify the effects of varying opioid prescribing patterns after surgery on dependence, overdose, or abuse in an opioid naive population.Retrospective cohort study.Surgical claims from a linked medical and pharmacy administrative database of 37 651 619 commercially insured patients between 2008 and 2016.1 015 116 opioid naive patients undergoing surgery.Use of oral opioids after discharge as defined by refills and total dosage and duration of use. The primary outcome was a composite of misuse identified by a diagnostic code for opioid dependence, abuse, or overdose.568 612 (56.0%) patients received postoperative opioids, and a code for abuse was identified for 5906 patients (0.6%, 183 per 100 000 person years). Total duration of opioid use was the strongest predictor of misuse, with each refill and additional week of opioid use associated with an adjusted increase in the rate of misuse of 44.0% (95% confidence interval 40.8% to 47.2%, P<0.001), and 19.9% increase in hazard (18.5% to 21.4%, P<0.001), respectively.Each refill and week of opioid prescription is associated with a large increase in opioid misuse among opioid naive patients. The data from this study suggest that duration of the prescription rather than dosage is more strongly associated with ultimate misuse in the early postsurgical period. The analysis quantifies the association of prescribing choices on opioid misuse and identifies levers for possible impact.
Efficacy, Predictive Factors, and Prediction Nomograms for 68 Ga-labeled Prostate-specific Membrane Antigen–ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy
Authors: Isabel Rauscher, Charlotte Düwel, Bernhard Haller, Christoph Rischpler, Matthias M. Heck, Jürgen E. Gschwend, Markus Schwaiger, Tobias Maurer, Matthias Eiber
Journal: European Urology (2018)
Abstract 16180: Use of CPR-sensing Defibrillators to Improve Outcomes for In-hospital Cardiac Arrest
Authors: Arash Harzand, Amit J Shah, A. Maziar Zafari
Journal: Circulation (2016)

Background: Survival among patients who suffer in-hospital cardiac arrest (IHCA) remains suboptimal, with currently reported survival to discharge rates of 9-38%. The use of real-time point-of-care...
Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics
Authors: Marlon Stoeckius, Shiwei Zheng, Brian Houck-Loomis, Stephanie Hao, Bertrand Z. Yeung, William M. Mauck, Peter Smibert, Rahul Satija
Journal: Genome biology (2018)

Despite rapid developments in single cell sequencing, sample-specific batch effects, detection of cell multiplets, and experimental costs remain outstanding challenges. Here, we introduce Cell Hashing, where oligo-tagged antibodies against ubiquitously expressed surface proteins uniquely label cells from distinct samples, which can be subsequently pooled. By sequencing these tags alongside the cellular transcriptome, we can assign each cell to its original sample, robustly identify cross-sample multiplets, and "super-load" commercial droplet-based systems for significant cost reduction. We validate our approach using a complementary genetic approach and demonstrate how hashing can generalize the benefits of single cell multiplexing to diverse samples and experimental designs.
Smoking and health: a physician's responsibility. A statement of the joint committee on smoking and health. American College of Chest Physicians, American Thoracic Society, Asia Pacific Society of Respirology, Canadian Thoracic Society, European Respiratory Society, International Union Against Tuberculosis and Lung Disease
Journal: European Respiratory Journal (1995)

Tobacco use, particularly cigarette smoking, is widely recognized by the medical community and the general public as a major public health problem.Physicians and medical organizations share a public health duty to address this problem.Physicians and their professional organizations must contribute effectively to measures undertaken to deal with cigarette smoking.The issues involved are complex and affect medical practice in a number of ways.The following statement, developed by six international organizations -the American College of Chest Physicians, the American Thoracic Society, the European Respiratory Society, the Asia Pacific Society of Respirology, the Canadian Thoracic Society, and the International Union Against Tuberculosis and Lung Disease -is intended to state the physicians responsibilities both to patients and to the community with regard to these general issues.
Detection of myositis-specific antibodies
Authors: Jean-Baptiste Vulsteke, Ellen De Langhe, Kristl G Claeys, Doreen Dillaerts, Koen Poesen, Jan Lenaerts, René Westhovens, Philip Van Damme, Daniel Blockmans, Petra De Haes, Xavier Bossuyt
Journal: Annals of the Rheumatic Diseases (2018)

It was with much interest that we read the recent European League Against Rheumatism/American College of Rheumatology classification criteria for idiopathic inflammatory myopathies.1 These criteria include Jo-1 autoantibodies, and the authors discussed that future updates of the criteria should also include the more recently identified myositis-specific autoantibodies.1 2 The interest in autoantibodies for classification is also illustrated by a recent proposal for a new clinicoserological classification of adult autoimmune myositis, which is based on the association of autoantibodies with distinct clinical phenotypes.3 4 For example, antibodies to synthetases (eg, Jo-1, PL-7 and PL-12) define the antisynthetase syndrome, anti-MDA-5 antibodies are associated with myositis with overlap features such as interstitial lung disease, anti-TIF-1γ and anti-NXP-2 define a subgroup of dermatomyositis and anti-SRP and anti-HMGCR are associated with necrotising autoimmune myositis.2

As autoantibodies play a role in the newly proposed classifications,1 …
Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology
Authors: Ikechi G. Okpechi, Mona Alrukhaimi, Gloria E. Ashuntantang, Ezequiel Bellorin-Font, Mohammed Benghanem Gharbi, Branko Braam, John Feehally, David C. Harris, Vivekanand Jha, Kailash Jindal, David W. Johnson, Kamyar Kalantar-Zadeh, Rumeyza Kazancioglu, Adeera Levin, Meaghan Lunney, Timothy Olusegun Olanrewaju, Vlado Perkovic, Jeffrey Perl, Harun Ur Rashid, Eric Rondeau, Babatunde Lawal Salako, Arian Samimi, Laura Sola, Irma Tchokhonelidze, Natasha Wiebe, Chih-Wei Yang, Feng Ye, Alexander Zemchenkov, Ming-hui Zhao, Aminu K. Bello
Journal: Kidney International Supplements (2018)
Use of a Hemoglobin Substitute (HBOC-201) to Treat Acute Anemia in a Leukemic Patient with Anti-Vel Antibodies
Authors: M. Tayyeb Ayyoubi, Suresh Manapuram, Hamza Hashmi, Katherine McDaniel, Soumit K. Basu, William Tse, Maxwell M. Krem
Journal: Blood (2017)
Abstract 14959: RNA-Seq Analysis of Peripheral Blood Monocyte Gene Expression Before and After Cardiac Resynchronization Therapy
Authors: Kenneth C Bilchick, Lingjin Meng, James Garmey, Coleen A McNamara
Journal: Circulation (2015)

Introduction: Cardiac resynchronization therapy (CRT) management could be improved with a better understanding of physiological pathways associated with improved responses, but routine myocardial tissue assessment is not feasible because of risks associated with cardiac biopsies. RNA analysis of peripheral blood monocytes (PBMCs) may be a promising alternative. Hypothesis: CRT responders have a unique gene expression profile in circulating PBMCs compared with nonresponders. Methods: RNA-Seq analysis of PBMCs was performed in n=14 patients before CRT and at a median 2.05 years after initial CRT implantation in responders and surviving nonresponders. Responders had at least a 15% reduction in left ventricular end-systolic volume and at least a 2 ml/kg/minute improvement in peak VO 2 after CRT. Polymerase chain reaction (PCR) was used to confirm changes in selected genes of interest. Results: Responders exhibited many changes not seen in nonresponders, particularly in key pathways including immune system and cytokine signaling; apoptosis and the cell cycle; phospholipid metabolism; glucose metabolism including glycolysis; gluconeogenesis and pyruvate metabolism including the tricarboxylic acid (TCA) cycle; NF kappa beta signaling; tubular function; transforming growth factor-beta signaling; and the response to oxidative stress. 2,365 genes had significant changes in responders (p&lt;0.05 after adjustment for multiple comparisons) but not nonresponders. Of these genes, 413 had at least a 2-fold change post-CRT, 322 had fold changes between 2 and 4, 88 had fold changes between 4 and 8, and 3 had fold changes greater than 8. PCR of a selected set of these genes linked to improved cardiac function confirmed RNA-Seq results. Conclusions: RNA-Seq analysis of PBMCs after CRT demonstrates many genes in key pathways with significant changes in responders but not nonresponders. These methods may be particularly useful in assessing prognosis after CRT.
Abstract 18890: Comparison of Cardiovascular Surgical Outcomes With Pediatric Cardiology and Cardiovascular Surgical Program Rankings Published in the Lay Press
Authors: David A Danford, John A Spertus, Shelby Kutty
Journal: Circulation (2017)

Introduction: Quality of care in pediatric cardiology and cardiovascular surgical programs is highly valued by the public, but the most common method for assessing quality is published rankings, su...
Individualised perioperative open-lung approach versus standard protective ventilation in abdominal surgery (iPROVE): a randomised controlled trial
Authors: Carlos Ferrando, Marina Soro, Carmen Unzueta, Fernando Suarez-Sipmann, Jaume Canet, Julián Librero, Natividad Pozo, Salvador Peiró, Alicia Llombart, Irene León, Inmaculada India, Cesar Aldecoa, Oscar Díaz-Cambronero, David Pestaña, Francisco J Redondo, Ignacio Garutti, Jaume Balust, Jose I García, Maite Ibáñez, Manuel Granell, Aurelio Rodríguez, Lucía Gallego, Manuel de la Matta, Rafael Gonzalez, Andrea Brunelli, Javier García, Lucas Rovira, Francisco Barrios, Vicente Torres, Samuel Hernández, Estefanía Gracia, Marta Giné, María García, Nuria García, Lisset Miguel, Sergio Sánchez, Patricia Piñeiro, Roger Pujol, Santiago García-del-Valle, José Valdivia, María J Hernández, Oto Padrón, Ana Colás, Jaume Puig, Gonzalo Azparren, Gerardo Tusman, Jesús Villar, Javier Belda, Jesús Acosta, Gerardo Aguilar, María José Alberola, Amalia Alcón, Jose M. Alonso, María Dolores Alonso, Rafael Anaya, María Pilar Argente, Marta Agilaga, Blanca Arocas, Ana Asensio, Begoña Ayas, Mercedes Ayuso, Victor Balandrón, María Barrio, Natalia Bejarano, Inmaculada Benítez, Sergio Cabrera, Jose A. Carbonell, Albert Carramiñana, Juan Carrizo, Virginia Cegarra, Estefanía Chamorro, Pedro Charco, Patricia Cruz, Francisco Daviu, Mario De Fez, Ángeles De Miguel, Elena Del Río, Carlos Delgado, Ruben Díaz, Susana Díaz, Fernando Díez, Rosa Dosdá, Alejandro Duca, Ma Justina Etulain, Carmen Fernández, Tania Franco, Isabel Fuentes, Clara Gallego, Alberto Gallego-Casilda, Ana Isabel Galve, Cristina Garcés, Mercedes García, Pablo García, Beatriz Garrigues, Vicente Gilabert, Domingo González, Andrea Gutiérrez, Inmaculada Hernández, Ana Izquierdo, Ana Jurado, Antonio Katime, Eduardo Llamazares, Rosa Lardies, Cristina Lisbona, Daniel López-Herrera, Ramiro López, Angels Lozano, Elena Lozano, Jose Miguel Marcos, Silvia Martin, Nilda Martínez, Rocío Martínez, Graciella Martínez-Pallí, Guido Mazzinari, Amanda Miñana, Victoria Moral, Tania Moreno, Ana Mugarra, Lorena Muñoz, Jose Navarro, Luis Olmedilla, Jonathan Olmedo, Nazario Ojeda, Ana Parera, María Parra, Cristina Parrilla, Ernesto Pastor, Natalia Peña, Ana María Pérez, Jose María Pérez, Laura Piqueras, Jesús Rico-Feijoo, Rayco Rodríguez, Javier Ignacio Román, Antonio Romero, Carolina Romero, Esther Romero, Isabel Ruiz, Ester Sánchez, Francisco Sandín, Ferran Serralta, Tania Socorro, Laura Soriano, Manuel Tisner, Lucia Valencia, Paola Valls, Laura Vaquero, Viviana Varón, María Vila, Rubén Villazala, Abigail Villena, Sara Zapatero
Journal: The Lancet Respiratory Medicine (2018)